Your session is about to expire
← Back to Search
Pembrolizumab for Bladder Cancer
Study Summary
This study is evaluating whether paclitaxel and pembrolizumab works better than paclitaxel alone in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body.
- Bladder Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are people currently able to sign up for this clinical trial?
"Unfortunately, this trial has already collected the number of participants needed for the study. The clinical trial was first posted on April 6th, 2016 and most recently edited on September 26th, 2022. For those still interested in participating in trials, there are currently 2598 studies actively looking for patients with carcinoma, transitional cell and 1771 studies for Pembrolizumab actively recruiting participants."
Is Pembrolizumab a new medication?
"Pembrolizumab is being trialled in 1771 studies globally, with 330 of those trials currently in Phase 3. The drug is being tested across 75216 locations, with a significant number of those trials taking place in Shanghai, China."
How many study subjects are enrolled at this time?
"Unfortunately, this particular clinical trial is no longer recruiting patients. However, there are currently 2598 trials for carcinoma, transitional cell and 1771 studies for Pembrolizumab that are still enrolling participants."
What are the potential dangers of Pembrolizumab to patients?
"Pembrolizumab falls into the Phase 2 category, which means that while there is some data suggesting it is safe, none of the trials thus far have shown that it is an effective medication."
Pembrolizumab is most commonly given to treat which type of cancer?
"Pembrolizumab is frequently prescribed to those with unresectable melanoma. It has also been found to be effective in treating microsatellite instability high, patients at a high risk of disease recurrence, and disease itself."
Share this study with friends
Copy Link
Messenger